| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Laboratory Corporation of America Holdings (NYSE: LH)
LH Technical Analysis
5
| As on 9th Jun 2023 LH STOCK Price closed @ 217.57 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 250.59 & Strong Sell for SHORT-TERM with Stoploss of 279.84 we also expect STOCK to react on Following IMPORTANT LEVELS. |
LHSTOCK Price
| Open | 219.18 | Change | Price | % |
| High | 219.67 | 1 Day | -3.17 | -1.44 |
| Low | 216.97 | 1 Week | 5.04 | 2.37 |
| Close | 217.57 | 1 Month | -7.12 | -3.17 |
| Volume | 447200 | 1 Year | -85.02 | -28.10 |
| 52 Week High 314.21 | 52 Week Low 204.30 | ||||
NYSE USA Most Active Stocks
| DDR | 15.44 | -4.46% |
| NIO | 7.73 | -0.77% |
| TWTR | 53.70 | 0.66% |
| CVNA | 19.07 | -21.30% |
| BACA-U | 302.00 | 0.67% |
| PLTR | 15.02 | -1.12% |
| F | 13.74 | 1.18% |
| CS | 0.89 | 1.14% |
| RPAI | 13.15 | -3.17% |
| AUY | 5.85 | -0.68% |
NYSE USA Top Gainers Stocks
NYSE USA Top Losers Stocks
| LH Daily Charts |
LH Intraday Charts |
Whats New @ Bazaartrend |
LH Free Analysis |
|
|
LH Important Levels Intraday
| RESISTANCE | 222.77 |
| RESISTANCE | 221.10 |
| RESISTANCE | 220.07 |
| RESISTANCE | 219.04 |
| SUPPORT | 216.10 |
| SUPPORT | 215.07 |
| SUPPORT | 214.04 |
| SUPPORT | 212.37 |
LH Forecast April 2024
| 4th UP Forecast | 279.29 |
| 3rd UP Forecast | 259.5 |
| 2nd UP Forecast | 247.26 |
| 1st UP Forecast | 235.03 |
| 1st DOWN Forecast | 200.11 |
| 2nd DOWN Forecast | 187.88 |
| 3rd DOWN Forecast | 175.64 |
| 4th DOWN Forecast | 155.85 |
LH Weekly Forecast
| 4th UP Forecast | 275.30 |
| 3rd UP Forecast | 256.79 |
| 2nd UP Forecast | 245.34 |
| 1st UP Forecast | 233.90 |
| 1st DOWN Forecast | 201.24 |
| 2nd DOWN Forecast | 189.80 |
| 3rd DOWN Forecast | 178.35 |
| 4th DOWN Forecast | 159.84 |
LH Forecast2024
| 4th UP Forecast | 442.74 |
| 3rd UP Forecast | 370.53 |
| 2nd UP Forecast | 325.89 |
| 1st UP Forecast | 281.25 |
| 1st DOWN Forecast | 153.89 |
| 2nd DOWN Forecast | 109.25 |
| 3rd DOWN Forecast | 64.61 |
| 4th DOWN Forecast | -7.6 |
Laboratory Corporation of America Holdings ( NYSE USA Symbol : LH )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
LH Business Profile
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company has a collaboration agreement with community clinical oncology research network, LLC to understand the impact of disparities in precision medicine for people with cancer; and strategic collaboration with GeneCentric Therapeutics, Inc. It serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina. Address: 531 South Spring Street, Burlington, NC, United States, 27215
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service